BRAINSWAY LTD/S (NASDAQ:BWAY) Expected to Post Quarterly Sales of $5.30 Million
Analysts predict that BRAINSWAY LTD/S (NASDAQ:BWAY) will announce $5.30 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BRAINSWAY LTD/S’s earnings. The firm is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that BRAINSWAY LTD/S will report full year sales of $22.35 million for the current fiscal year, with estimates ranging from $22.30 million to $22.40 million. For the next financial year, analysts expect that the firm will report sales of $30.00 million, with estimates ranging from $29.50 million to $30.50 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last released its earnings results on Wednesday, May 29th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.00 million.
BWAY stock traded down $0.10 during midday trading on Thursday, reaching $10.00. The company had a trading volume of 3,200 shares, compared to its average volume of 14,387. BRAINSWAY LTD/S has a 1 year low of $8.00 and a 1 year high of $12.39. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average price is $9.93.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Story: Why is the price-sales ratio important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.